These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30630730)

  • 41. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.
    Hayashi K; Mitani S; Taniguchi H; Yasui H; Muro K; Mori K; Gotoda T; Yamazaki K
    Oncology; 2019; 96(3):132-139. PubMed ID: 30359979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.
    Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.
    Sastre J; Massuti B; Pulido G; Guillén-Ponce C; Benavides M; Manzano JL; Reboredo M; Rivera F; Grávalos C; Safont MJ; Martínez Villacampa M; Llovet P; Dotor E; Díaz-Rubio E; Aranda E;
    Eur J Cancer; 2015 Jul; 51(11):1371-80. PubMed ID: 25963019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
    Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
    Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
    Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
    Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
    Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
    J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.
    Gouverneur A; Claraz P; Rousset M; Arnaud M; Fourrier-Réglat A; Pariente A; Aparicio T; Miremont-Salamé G; Noize P
    Target Oncol; 2017 Dec; 12(6):805-814. PubMed ID: 29022151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
    Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
    Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
    Ward P; Hecht JR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Naeim A
    J Geriatr Oncol; 2014 Oct; 5(4):368-75. PubMed ID: 25002322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
    Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
    Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life.
    Gouverneur A; Bezin J; Jové J; Bosco-Lévy P; Fourrier-Réglat A; Noize P
    J Am Geriatr Soc; 2019 May; 67(5):913-919. PubMed ID: 30840323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    Landre T; Maillard E; Taleb C; Ghebriou D; Guetz GD; Zelek L; Aparicio T
    Int J Colorectal Dis; 2018 Aug; 33(8):1125-1130. PubMed ID: 29680896
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials.
    Oweira H; Giryes A; Mannhart M; Decker M; Abdel-Rahman O
    Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):1069-1074. PubMed ID: 30099922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.